Cohance Lifesciences Intrinsic Value

Cohance Lifesciences intrinsic value. Cohance Lifesciences (COHANCE) median intrinsic value is ₹505.26 from 8 valuation models (range ₹138–₹1149), vs current price ₹459.45 — +10.0% upside (Trading Near Calculated Value), margin of safety 9.1%. For current market price and key ratios, visit Cohance Lifesciences share price screener.

Market Price (CMP)
₹459.45
Primary Intrinsic Value
₹137.83
Market Cap
₹1746 Cr
+10.0% Upside
Median Value
₹505.26
Value Range
₹138 - ₹1149
Assessment
Trading Near Calculated Value
Safety Margin
9.1%

COHANCE Valuation Methods Summary — DCF, Graham Number & P/E

Cohance Lifesciences intrinsic value across 8 models vs current price ₹459.45 — upside/downside and value range per method. Analyse Cohance Lifesciences ownership pattern to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹137.83 ₹110.26 - ₹165.40 -70.0% EPS: ₹1.60, Sector P/E: 22x
Book Value Method asset ₹1148.62 ₹1033.76 - ₹1263.48 +150.0% Book Value/Share: ₹1061.58, P/B: 2.0x
Revenue Multiple Method revenue ₹918.90 ₹827.01 - ₹1010.79 +100.0% Revenue/Share: ₹514.74, P/S: 2.0x
EBITDA Multiple Method earnings ₹505.26 ₹454.73 - ₹555.79 +10.0% EBITDA: ₹192.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹823.47 ₹658.78 - ₹988.16 +79.2% CF Growth: 2.8%, Discount: 15%
PEG Ratio Method growth ₹137.83 ₹124.05 - ₹151.61 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹137.83 ₹124.05 - ₹151.61 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
Graham Defensive Method conservative ₹195.49 ₹175.94 - ₹215.04 -57.5% EPS: ₹1.60, BVPS: ₹1061.58
Method Types: Earnings Asset DCF Growth Dividend Conservative

COHANCE Intrinsic Value vs Market Price — All Valuation Models

Cohance Lifesciences fair value range ₹138–₹1149 vs current market price ₹459.45 across 8 valuation models. Browse COHANCE cash flow statement for revenue, profit, balance sheet and cash flow data.

COHANCE Intrinsic Value Analysis — Undervalued or Overvalued?

Cohance Lifesciences median intrinsic value ₹505.26, current price ₹459.45 — Trading Near Calculated Value by 10.0%, margin of safety 9.1%.

What is the intrinsic value of COHANCE?

Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Cohance Lifesciences (COHANCE) is ₹505.26 (median value). With the current market price of ₹459.45, this represents a +10.0% variance from our estimated fair value.

The valuation range spans from ₹137.83 to ₹1148.62, indicating ₹137.83 - ₹1148.62.

Is COHANCE undervalued or overvalued?

Based on our multi-method analysis, Cohance Lifesciences (COHANCE) appears to be trading near calculated value by approximately 10.0%.

COHANCE Financial Health — Key Ratios vs Industry Benchmarks

Cohance Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 0.2% Industry Standard: 15%+ Below 10% Measures shareholder return efficiency
Operating Margin 7.0% Industry Standard: 20%+ Below 10% Indicates operational efficiency level
Asset Turnover Ratio 0.34x Industry Standard: 1.0x+ Below 0.5x Measures asset utilization efficiency

COHANCE Cash Flow Quality — Operating & Free Cash Flow

Cohance Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹368 Cr ₹243 Cr Positive Free Cash Flow 8/10
March 2025 ₹673 Cr ₹479 Cr Positive Free Cash Flow 8/10
March 2024 ₹359 Cr ₹178 Cr Positive Free Cash Flow 7/10
March 2023 ₹457 Cr ₹360 Cr Positive Free Cash Flow 8/10
March 2022 ₹330 Cr ₹262 Cr Positive Free Cash Flow 8/10